The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 110-119

  Hayman, Thomas J ^a,b   Wahba, Amy ^b   Rath, Barbara H ^b   Bae, Heekyong ^b   Kramp, Tamalee ^b   Shankavaram, Uma T ^b   Camphausen, Kevin ^b   Tofilon, Philip J ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; INK 128; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA TRANSLATION; TUMOR GROWTH;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZOXAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PYRIMIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892156262     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2136     Document Type: Article

References (30)

1. Lu X, de la Pena L, Barker C, Camphausen K, Tofilon PJ. Radiationinduced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res 2006; 66:1052-61.
2. Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lu X, Camphausen K, Tofilon PJ. Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res 2008;68:3819-26.
3. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res 2012;72:2362-72.
4. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
5. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
6. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of m TOR inhibitors. Nat Rev Drug Discov 2011;10:868-80.
7. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010;16:4914-20.
8. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009;8:567-72.
9. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38.
10. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenicm TOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-61.
11. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32.
12. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010;70:621-31.
13. Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ. Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity. Transl Oncol 2013;6:355-62.
14. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
15. ClinicalTrials.gov [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2013 Jun 1]. Available from: http://clinicaltrials.gov/.
16. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012; 72:282-93.
17. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
18. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708.
19. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
20. Bellizzi AM, Bloomston M, Zhou XP, Iwenofu OH, Frankel WL. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl Immunohistochem Mol Morphol 2010;18:442-7.
21. Bae H, Gray JS, Li M, Vines L, Kim J, Pestka JJ. Hematopoietic cell kinase associates with the 40S ribosomal subunit and mediates the ribotoxic stress response to deoxynivalenol in mononuclear phagocytes. Toxicol Sci 2010;115:444-52.
22. Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri FR, et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia 2010;12:848-55.
23. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105:17414-9.
24. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. Gamma H2 AX and cancer. Nat Rev Cancer 2008;8:957-67.
25. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, et al. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010; 9:662-9.
26. Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 2012;109:8977-82.
27. Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 2011;105:329-36.
28. Braunstein S, Badura ML, Xi Q, Formenti SC, Schneider RJ. Regulation of protein synthesis by ionizing radiation. Mol Cell Biol 2009;29:5645-56.
29. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
30. Badura M, Braunstein S, Zavadil J, Schneider RJ. DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proc Natl Acad Sci U S A 2012;109:18767-72.